TEMOVATE E
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TEMOVATE E (TEMOVATE E).
Topical corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Mildly absorbed percutaneously; metabolized in the liver via CYP3A4; excreted renally and biliary. |
| Excretion | Primarily hepatic metabolism; renal excretion of metabolites (<5% unchanged). Biliary/fecal elimination accounts for a minor fraction. |
| Half-life | Terminal elimination half-life: approximately 1.5-3 hours (topical application). Clobetasol propionate is rapidly cleared, minimizing systemic accumulation with short-term use. |
| Protein binding | Approximately 96-99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Not well characterized for topical formulation; estimated Vd ~0.5 L/kg based on systemic absorption data. Reflects distribution into extracellular fluid and tissues. |
| Bioavailability | Topical: Low systemic bioavailability (~1-7%) due to high potency and limited percutaneous absorption; enhanced by occlusion or damaged skin. |
| Onset of Action | Topical: Improvement may be noted within 2-3 days of twice-daily application, with measurable vasoconstriction as early as 2-4 hours. |
| Duration of Action | Therapeutic effect lasts 12-24 hours after single application, supporting twice-daily dosing. Continued treatment for up to 2 consecutive weeks is recommended for chronic conditions. |
| Molecular Weight | 466.97 |
Apply a thin layer to the affected skin areas once daily. Not for use for more than 2 consecutive weeks. Use no more than 50 g per week. Not for use in children under 12 years.
| Dosage form | CREAM |
| Renal impairment | No specific dosing adjustment required for renal impairment. Use with caution in patients with severe renal impairment due to possible systemic absorption. |
| Liver impairment | No specific dosing adjustment required for hepatic impairment. However, due to potential for systemic absorption, caution is advised in patients with severe hepatic impairment. |
| Pediatric use | Not recommended for use in pediatric patients under 12 years due to higher risk of HPA axis suppression. For children 12 years and older, use same as adult dosing but limit to shortest duration possible, typically no more than 2 weeks. |
| Geriatric use | No specific dose adjustment needed. Use with caution due to increased likelihood of skin thinning and systemic absorption. Limit use to shortest duration possible and avoid occlusive dressings. |
| 1st trimester | Topical corticosteroids like clobetasol propionate are generally avoided during the first trimester due to potential association with orofacial clefts, though data is limited. Use only if clearly needed. |
| 2nd trimester | Use with caution; prolonged or high-dose use may lead to low birth weight. Avoid large areas, occlusive dressings, or prolonged treatment. |
| 3rd trimester | Use with caution as systemic absorption may cause fetal adrenal suppression or growth retardation. Avoid use near term. |
Clinical note
Comprehensive clinical and safety monograph for TEMOVATE E (TEMOVATE E).
| Placental transfer | Clobetasol propionate is a potent corticosteroid that crosses the placenta in small amounts, but significant fetal exposure is unlikely with topical use. Systemic absorption increases with larger surface areas or occlusive dressings. |
| Breastfeeding | Topical application to limited areas is likely compatible with breastfeeding, but avoid application to the breast or nipple area to prevent infant ingestion. Systemic absorption is minimal with short-term use. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
Hypersensitivity to clobetasol propionate or any component of the formulationUntreated bacterial, fungal, or viral skin infectionsRosaceaPerioral dermatitis
| Precautions | Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and unmask latent diabetes; avoid use on face, groin, axillae, or intertriginous areas; do not use with occlusive dressings; local irritation and atrophy possible. |
| Food/Dietary | No specific food interactions are known with topical clobetasol propionate. No dietary restrictions are required. |
Loading safety data…
| Lactation Rating | L2 (Limited data - probably compatible) |
| Teratogenic Risk | Topical corticosteroids like TEMOVATE E (clobetasol propionate) are classified as Pregnancy Category C. Animal studies have shown teratogenicity with topical corticosteroids, but there are no adequate and well-controlled studies in pregnant women. Systemic absorption after topical application is low; however, risks cannot be excluded. Use only if potential benefit justifies risk to fetus. First trimester: avoid unless necessary. Second and third trimesters: use lowest potency for shortest duration. |
| Fetal Monitoring | Monitor for signs of hypothalamic-pituitary-adrenal (HPA) axis suppression in the mother if large areas are treated or occlusive dressings used. In fetus/newborn, watch for potential adrenal suppression if prolonged maternal use. No specific fetal monitoring required with brief, limited topical use. |
| Fertility Effects | No human studies on fertility effects. Animal studies with topical corticosteroids have shown no impairment of fertility at low systemic doses. Systemic absorption from topical use is minimal, so effects on fertility are expected to be negligible. |
| Clinical Pearls |
| Temovate E (clobetasol propionate emollient 0.05%) is a super-high potency corticosteroid for short-term treatment of moderate to severe corticosteroid-responsive dermatoses. Limit continuous use to 2 weeks and total dosage to 50 g/week due to risk of HPA axis suppression. Avoid application to face, groin, axillae, or intertriginous areas. Use only in patients aged 12 years or older. |
| Patient Advice | Apply a thin layer to affected areas once or twice daily as directed. · Do not cover the treated area with bandages or dressings unless instructed by your doctor. · Avoid use on the face, underarms, or groin area unless your doctor specifically tells you to. · Do not use this medication for longer than 2 consecutive weeks. · Do not use more than 50 grams per week. · Wash hands after application unless treating the hands. · Inform your doctor if your condition persists or worsens after 2 weeks of treatment. · Avoid contact with eyes. If contact occurs, rinse thoroughly with water. · Do not use this medication in children under 12 years old. |